Antikor Biopharma Limited

Antikor Biopharma is pioneering an innovative drug delivery technology called OptiLink, specifically-tailored for solid tumours. It is unique by utilising optimally-engineered, small-format, tumour-specific antibodies with appropriately-designed linkers to deliver therapeutic payloads deep into tumours. Unlike its competitors, who use full-size antibody-d...

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink, tailored for solid tumours. It is unique by utilising specially-engineered, small-format, tumour-specific antibodies with appropriately-designed linkers to specifically deliver potent cytotoxic payloads deep into tumours. Unlike its competitors, who use full-size antibod...

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink. It harnesses the immune system by using tumour-seeking antibodies to specifically deliver potent cytotoxic payloads to tumours. Unlike its competitors, who use full antibody-drug conjugates (ADCs), Antikor's technology enables much smaller fragment-drug conjugates (FDCs)...

no public description

The COVID-19 pandemic is the 3rd-known coronaviral-disease with an alarmingly-high transmission rate. These incidences will keep returning and we must be prepared with innovative technologies to combat future epidemics/pandemics. Vaccinations are the gold-standard but this may not always be successful and can have adverse effects and/or lead to incomplete...

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink. It harnesses the immune system by using miniaturised tumour-specific antibodies to specifically deliver high quantities of potent cytotoxic payloads to tumours. Unlike its competitors, who use full antibody-drug conjugates (ADCs), Antikor's technology enables much smalle...

"Antikor is developing a novel and disruptive platform for oncology drug delivery called **Fragment Drug Conjugates (FDC)**. Here, cytotoxic payloads are specifically delivered to solid tumours. Our platform differentiates from other similar Antibody Drug Conjugates (ADC) approaches in that our format can penetrate tumours faster and more effectively, del...

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink. It harnesses the immune system by using tumour-seeking antibodies to specifically deliver potent cytotoxic payloads to tumours. Unlike its competitors, who use full antibody-drug conjugates (ADCs), Antikor’s technology enables much smaller fragment-drug conjugates (FDCs)...

Antibody drug conjugates (ADCs) are a new wave of targeted cancer therapies that promise dramatically increased survival with significantly lower side effects. Potent toxic “payloads” are attached to tumour-cell specific targeting vehicles called antibodies. This is an early technology with only 2 approved products. There is still a need to develop improv...

Gastric cancer is a major unmet clinical need and a significant business opportunity. Treatment options are few and endoscopic investigation and treatment need advances to improve success rates and patient survival. PhotoBiotics Ltd, University College London's (UCL)-Chemistry and UCL's-National Medical Laser Centre are strengthening their partnership wit...

Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These ...

PhotoBiotics is a biotechnology company established from Imperial College London to develop antibody drug conjugates (ADCs) to treat cancer and other associated diseases. Its patented OptiLink platform enables high drug loading of small antibody fragments leading to enhanced formulation, tumour specificity, reduced side effects and high potency. In this T...